Kings Path Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Kings Path Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$513K	Hold	6,200	–	–	0.14%	65
2026 Q1	$489K	Hold	6,200	–	–	0.17%	58
2025 Q4	$489K	Buy	6,200 +985	+19%	+$85.3K	0.17%	58
2025 Q3	$478K	Sell	5,215 -4,847	-48%	-$395K	0.18%	59
2025 Q2	$657K	Sell	10,062 -1,851	-16%	-$121K	0.26%	46
2025 Q1	$798K	Sell	11,913 -7,505	-39%	-$448K	0.39%	39
2024 Q4	$1.07M	Hold	19,418	–	–	0.46%	53
2024 Q3	$1.16M	Buy	19,418 +3,086	+19%	+$188K	0.49%	50
2024 Q2	$1.04M	Buy	+16,332	New	+$1.06M	0.49%	52

Other funds holding ANIP

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Kings Path Partners's ANIP Position: Q2 2026 in Review

Kings Path Partners held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 6,200 shares worth $513K. The position accounts for 0.14% of the portfolio, ranked #65.

Kings Path Partners first reported a position in ANIP in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.16M in Q3 2024. 23 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Kings Path Partners held 6,200 shares of ANI Pharmaceuticals worth $513K as of Q2 2026.
Kings Path Partners left its ANI Pharmaceuticals share count unchanged in Q2 2026.
ANI Pharmaceuticals made up 0.14% of Kings Path Partners's portfolio in Q2 2026, its #65 holding.
Kings Path Partners first reported a position in ANI Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Kings Path Partners's ANI Pharmaceuticals position peaked at $1.16M in Q3 2024.
23 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Kings Path Partners's 13F filing for Q2 2026, filed 14 Jul 2026.